嵌合抗原受体 T 细胞在多发性骨髓瘤治疗中的应用。
Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.
机构信息
Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA.
Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, 3400 Civic Center Boulevard, 12th Floor South Tower, Philadelphia, PA 19104, USA.
出版信息
Hematol Oncol Clin North Am. 2024 Apr;38(2):383-406. doi: 10.1016/j.hoc.2023.12.004. Epub 2023 Dec 28.
Chimeric antigen receptor T cells (CARTs) represent another powerful way to leverage the immune system to fight malignancy. Indeed, in multiple myeloma, the high response rate and duration of response to B cell maturation antigen-targeted therapies in later lines of disease has led to 2 Food and Drug Administration (FDA) drug approvals and opened the door to the development of this drug class. This review aims to provide an update on the 2 FDA-approved products, summarize the data for the most promising next-generation multiple myeloma CARTs, and outline current challenges in the field and potential solutions.
嵌合抗原受体 T 细胞（CARTs）代表了另一种利用免疫系统对抗恶性肿瘤的强大方法。事实上，在多发性骨髓瘤中，针对 B 细胞成熟抗原的靶向治疗在疾病后期的高反应率和反应持续时间，导致了 2 种食品和药物管理局（FDA）药物的批准，并为这类药物的开发打开了大门。本综述旨在提供关于 2 种 FDA 批准产品的最新信息，总结最有前途的新一代多发性骨髓瘤 CART 的数据，并概述该领域当前的挑战和潜在的解决方案。
Zotero 插件